Dr. Floor Backes, MD
Claim this profileOhio State University Comprehensive Cancer Center
Expert in Cancer
Expert in Ovarian Cancer
22 reported clinical trials
60 drugs studied
About Floor Backes, MD
Education:
- Obtained MD from Ohio State University College of Medicine in 2015.
- Completed Residency in Internal Medicine at The Ohio State University Wexner Medical Center in 2018.
- Finished Fellowship in Hematology and Oncology at Ohio State University Comprehensive Cancer Center in 2021.
Experience:
- Currently serves as an Assistant Professor in the Division of Medical Oncology at Ohio State University Comprehensive Cancer Center.
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Ovarian Cancer
Global LeaderStage IV
Stage III
BRCA1 positive
Affiliated Hospitals
Clinical Trials Floor Backes, MD is currently running
Mirvetuximab + Bevacizumab
for Ovarian Cancer
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Recruiting2 awards Phase 3
Selumetinib + Olaparib
for Ovarian and Endometrial Cancer
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting1 award Phase 2
More about Floor Backes, MD
Clinical Trial Related1 year of experience running clinical trials · Led 22 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Floor Backes, MD has experience with
- Paclitaxel
- Carboplatin
- Pembrolizumab
- Olaparib
- Letrozole
- Cisplatin
Breakdown of trials Floor Backes, MD has run
Cancer
Ovarian Cancer
Endometrial Cancer
Fallopian Tube Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Floor Backes, MD specialize in?
Floor Backes, MD focuses on Cancer and Ovarian Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Floor Backes, MD currently recruiting for clinical trials?
Yes, Floor Backes, MD is currently recruiting for 10 clinical trials in Columbus Ohio. If you're interested in participating, you should apply.
Are there any treatments that Floor Backes, MD has studied deeply?
Yes, Floor Backes, MD has studied treatments such as Paclitaxel, Carboplatin, Pembrolizumab.
What is the best way to schedule an appointment with Floor Backes, MD?
Apply for one of the trials that Floor Backes, MD is conducting.
What is the office address of Floor Backes, MD?
The office of Floor Backes, MD is located at: Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States. This is the address for their practice at the Ohio State University Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.